Abstract
Huntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve HD patients’ quality of life and enhance their survival. In this review we describe the symptomatic and neuroprotective therapies in HD that are currently in a preclinical or clinical stage. Neuroprotective therapies can act at several stages of HD, namely through: i) transcription modulation, ii) regulation of neurotrophic factors levels, iii) inhibition of metabolic dysfunction through metabolic enhancers, iv) apoptosis inhibition, v) autophagy regulation, vi) transglutaminase inhibition, and/or vii) modulation of neurotransmitter receptors. Moreover, emerging therapies in HD, including gene therapy using siRNA and shRNA to silence CAG repeats or deep brain stimulation, have shown promising results. Although most of the therapies are at a pre-clinical stage, phase II-III clinical trials have been performed for each pathophysiological mechanism of the disease. Thus, efforts should continue to ensure that effective therapies are studied and tested to help mitigate HD.
Keywords: Huntington disease, mutant huntingtin, neuroprotective therapy, symptomatic treatment.
Current Drug Targets
Title:Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Volume: 15 Issue: 3
Author(s): Ana C. Brett, Tatiana R. Rosenstock and A. Cristina Rego
Affiliation:
Keywords: Huntington disease, mutant huntingtin, neuroprotective therapy, symptomatic treatment.
Abstract: Huntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve HD patients’ quality of life and enhance their survival. In this review we describe the symptomatic and neuroprotective therapies in HD that are currently in a preclinical or clinical stage. Neuroprotective therapies can act at several stages of HD, namely through: i) transcription modulation, ii) regulation of neurotrophic factors levels, iii) inhibition of metabolic dysfunction through metabolic enhancers, iv) apoptosis inhibition, v) autophagy regulation, vi) transglutaminase inhibition, and/or vii) modulation of neurotransmitter receptors. Moreover, emerging therapies in HD, including gene therapy using siRNA and shRNA to silence CAG repeats or deep brain stimulation, have shown promising results. Although most of the therapies are at a pre-clinical stage, phase II-III clinical trials have been performed for each pathophysiological mechanism of the disease. Thus, efforts should continue to ensure that effective therapies are studied and tested to help mitigate HD.
Export Options
About this article
Cite this article as:
Brett C. Ana, Rosenstock R. Tatiana and Rego Cristina A., Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease, Current Drug Targets 2014; 15 (3) . https://dx.doi.org/10.2174/1389450114666131124140704
DOI https://dx.doi.org/10.2174/1389450114666131124140704 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?
Current Cancer Drug Targets Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry Surgical Repair Involving Tissue Flap Transplantation with Vascular Pedicle in Treating Refractory Pressure Ulcers Around Hip and Sacral Region
Current Signal Transduction Therapy Applications of Molecularly Imprinted Polymers for Isolation of Estrogens from Environmental Water Samples
Current Analytical Chemistry Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation
Current Pharmaceutical Design Neurovestibular and Sensorimotor Studies in Space and Earth Benefits
Current Pharmaceutical Biotechnology Exploring the Abnormal Signal Transduction Mediated Internet Addiction and Gaming Disorders
Current Signal Transduction Therapy The Hypocretins and their Role in Narcolepsy
CNS & Neurological Disorders - Drug Targets Cannabinoid Function in Spatial Learning: An Update
Current Neuropharmacology Commentary: The Effects of Psychological Stress on Microglial Cells in the Brain
CNS & Neurological Disorders - Drug Targets Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Long Term Ketamine and Ketamine Plus Alcohol Toxicity - What can we Learn from Animal Models?
Mini-Reviews in Medicinal Chemistry Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia
CNS & Neurological Disorders - Drug Targets Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy
Current Drug Targets - Infectious Disorders Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Current Psychopharmacology Plasma Rich in Growth Factors Enhances Wound Healing and Protects from Photo-oxidative Stress in Dermal Fibroblasts and 3D Skin Models
Current Pharmaceutical Biotechnology Carbonic Anhydrase Related Protein VIII and its Role in Neurodegeneration and Cancer
Current Pharmaceutical Design Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy Wnt Signaling Pathway in Schizophrenia
CNS & Neurological Disorders - Drug Targets